Literature DB >> 28655493

EEG with extreme delta brush in young female with methotrexate neurotoxicity supports NMDA receptor involvement.

Lisbeth Samsø Schmidt1, Troels W Kjær2, Kjeld Schmiegelow3, Alfred Peter Born4.   

Abstract

Sub-acute neurotoxicity is a well-known complication to high-dose and intrathecal methotrexate (MTX) treatment of children with leukemia. Symptoms can be treated safely by dextromethorphan, a non-competitive antagonist to N-methyl-D-aspartic acid receptor (NMDAR). In a female with subacute MTX neurotoxicity, we observed an electroencephalographic (EEG) with extreme delta brush. Extreme delta brush is an EEG pattern previously described in patients with NMDAR autoimmune encephalitis. The observations suggest that the mechanism of this neurotoxicity may be mediated by the NMDAR. Furthermore, extreme EEG delta brush should suggest a diagnosis of MTX associated subacute neurotoxicity.
Copyright © 2017 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ALL; EEG; Extreme delta brush; Methotrexate; NMDA receptor; Neurotoxicity

Mesh:

Substances:

Year:  2017        PMID: 28655493     DOI: 10.1016/j.ejpn.2017.05.008

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  2 in total

1.  A Case of HIV Seroconversion Presenting Similarly to Anti-N-methyl-D-aspartate Receptor Encephalitis.

Authors:  Heather VanDongen-Trimmer; Kumar Sannagowdara; Binod Balakrishnan; Raquel Farias-Moeller
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.532

2.  A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report.

Authors:  Dongmei Wang; Yongming Wu; Zhong Ji; Shengnan Wang; Yunqi Xu; Kaibin Huang; Yu Peng; Hui Zheng; Honghao Wang; Xiaomei Zhang; Suyue Pan
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.